REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Clinical trial NCT04526106 · COMPLETED

Trial details

NCT number: NCT04526106
Sponsor: Elevar Therapeutics
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

FGFR2 Amplification FGFR2 Gene Mutation FGFR2 Gene Fusion/Rearrangement FGFR2 Gene Translocation FGFR2 Gene Activation Intrahepatic Cholangiocarcinoma Cholangiocarcinoma Other Solid Tumors, Adult

Start date: 2020-09-02
Primary completion: 2025-09-05
Enrollment: 490

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.